Medscape is available in 5 Language Editions – Choose your Edition here.


Esthesioneuroblastoma Workup

  • Author: Michael Somenek, MD; Chief Editor: Jules E Harris, MD, FACP, FRCPC  more...
Updated: Apr 14, 2015

Laboratory Studies

No specific lab studies confirm the diagnosis of esthesioneuroblastoma (ENB). Because surgery often is contemplated and because open nasal procedures are associated with significant bleeding and may involve blood transfusions, a complete blood count may be obtained, and the patient should be advised about preoperative blood donation.


Imaging Studies

Computed Tomography

Standard radiographs do not have a role in the evaluation of esthesioneuroblastoma (ENB). A direct coronal fine-cut (3 mm) CT scan is the initial radiologic study of choice.

  • ENB lacks a specific radiologic appearance and is seen as a homogeneous soft tissue mass with uniform and moderate contrast enhancement, as depicted in the 1st image above.
  • CT images are essential for correct staging and should be evaluated carefully for erosion of the lamina papyracea, cribriform plate, and fovea ethmoidalis specifically.
  • Obstruction of the sinus-draining ostia results in an accumulation of nasal secretions, which tend to be difficult to differentiate from tumor tissue when viewed on CT scan.
  • An unusual but characteristic imaging feature of ENBs is the presence of cysts at the tumor-brain interface. [10]
  • An example image is shown below.
    Esthesioneuroblastoma. Coronal CT scan of the orbi Esthesioneuroblastoma. Coronal CT scan of the orbits and sinuses shows a large, enhancing, and expansile mass occupying the ethmoid air cells that is invading the cribriform plate and breaking through to the left anterior cranial fossa. Image courtesy of Michael Lev, MD.

Magnetic Resonance Imaging

MRI often is necessary to better delineate sinonasal and intraorbital extension or an intracerebral extension.

Using MRI, ENB appears as hypointense to gray matter on T1-weighted images and isointense or hyperintense to gray matter on T2-weighted images, as depicted in the second image above.

Because details of bony erosion are better demonstrated by CT images, both studies usually are required in the majority of patients.

An example image is shown below.

Esthesioneuroblastoma. A 39-year-old man presented Esthesioneuroblastoma. A 39-year-old man presented with 1 month of decreased vision, left facial numbness, and swelling. Physical examination demonstrated left-sided exophthalmos and blindness. He had also lost his sense of smell. Contrast-enhanced T1-weighted MRI demonstrated a large lesion that originated in the paranasal sinuses and extended through the cribriform plate into the anterior cranial fossa. He underwent a bifrontal craniotomy for resection of this tumor.


Since most ENBs express somatostatin receptors, the use of scintigraphy with a radiolabeled somatostatin analog (111 In-pentoctreotide [111 In-DTPA-D-pheoctreotide]; Octreoscan) has been proposed. A preliminary study of this technique found it to be clinically useful, especially for discriminating between postoperative changes and residual or recurrent tumor after extensive skull base surgery.[11] The sensitivity and specificity remain unclear, however.


Histologic Findings

Esthesioneuroblastomas (ENBs) can display various histologic presentations. The hallmark of well-differentiated ENBs is arrangements of cells into rosettes or pseudorosettes (sheets and clusters). True rosettes (Flexner-Wintersteiner rosettes) refer to a ring of columnar cells circumscribing a central oval-to-round space, which appears clear on traditional pathologic sections. Pseudorosettes (Homer-Wright rosettes) are characterized by a looser arrangement and the presence of fibrillary material within the lumen.

One common method of stratification is to separate ENBs into 2 distinct groups: neuroblastomas proper and neuroendocrine carcinomas. The first group, neuroblastomas proper, has a histologic presentation similar to that of peripheral neuroblastomas of childhood. This group of ENBs is composed of sheets of poorly demarcated groups of cells separated by fine connective tissue trabeculae. The cells are small and typically show no mitotic activity. Importantly, these masses contain fibrillary material between the cells. Rosettes of the Homer-Wright type are present. One observed feature on electron microscopy is the presence of a dendritic cytoplasmic process with accumulations of small dense core granules within the process.[12]

The unique feature of neuroendocrine carcinomas, the second class of ENBs, is admixture with glands. A neurofibrillary component is absent, and the growth pattern is that of solid nests without rosettes. In some cases, ENBs present as neoplastic cells that are intimately related to the basal epithelium of the glands, and a neurofibrillary component is not seen. The cells in these tumors are typically larger than those in neuroblastomas, and the growth pattern is that of solid nests without rosettes. Dense core granules similar to those of neuroblastoma are present in the cytoplasm and cytoplasmic extensions.

Further confounding accurate diagnosis is the fact that ENB is histologically similar to other small, round blue cell tumors. The acronym LEMONS ( lymphoma, Ewing sarcoma, melanoma, olfactory/ other [ENBs, rhabdomyosarcoma or Markel cell carcinoma], neuroblastoma, and small cell carcinoma) defines the other tumors from which ENB should be differentiated. Distinguishing ENBs from the other tumors is of paramount importance because the tumors respond differently to various treatment modalities.

The following list describes the outcome of each of these diseases with various

immunohistochemical tests.

  • Esthesioneuroblastomas stain positive for S-100 protein and/or neuron-specific enolase, while the stain usually is negative for cytokeratin, desmin, vimentin, actin, glial fibrillary acidic protein, UMB 45, and the common leukocytic antigen. For difficult cases, electron microscopy can be useful. Common features are small, round neuroepithelial cells arranged in rosette or pseudorosette patterns, separated by fibrous elements. Rosettes consist of a central space ringed by columnar cells with radially oriented nuclei.
  • Lymphoma can be excluded when the majority of tumor cells are negative for CD45 (the remaining positive cells demonstrate no atypical immunophenotype).
  • Ewing sarcoma is positive for MIC2/CD99 gene products that result from an 11;22 translocation. [13]
  • Melanoma can be identified using a combination of immunohistochemical markers: MART-1/Melan-A, HMB-45, and S-100. S-100 is expressed in more than 95% of melanomas.
  • Rhabdomyosarcoma displays a loss of chromosome 11 and stains positive for desmin (expressed in 95%), muscle-specific actin, and myoglobin.
  • Markel cell carcinoma stains positively for low-molecular-weight cytokeratin 20 and NSE.
  • Neuroblastoma often stains positive for NSE, synaptophysin, Leu7, and neurofilament protein. Elevated serum catecholamines are also suggestive of neuroblastoma.
  • Small cell carcinomas stain positively for chromogranin, NSE, and synaptophysin (presynaptic nerve cell vesicles). Most small cell carcinomas are positive for TTF-1.

In summary, the pathologic distinction of poorly differentiated small neoplasms of the nasal cavity is difficult and is based on a panel of immunohistochemical stains and, if necessary, electron microscopy. To date, no specific immunocytologic stain identifies ENB; however, knowledge of the histochemistry of other related tumors can distinguish them. When ENB is suspected, diagnostic tests should include S-100 protein, neuron-specific enolase, chromogranin and/or synaptophysin, cytokeratin, desmin, actin, UMB 45, common leukocytic antigen, and myc-2 protein.

ENB can be graded histologically by the Hyams system, which is based on the preservation of lobular architecture, mitotic index, nuclear polymorphism, and the presence of fibrillary matrix, rosettes, and necrosis.[14] The Hyams system is based on 4 grades, which are described in Table 1, below.

Table. Histopathologic Grading According to Hyams[14] (Open Table in a new window)

Grade Lobular Architecture Preservation Mitotic Index Nuclear Polymorphism Fibrillary Matrix Rosettes Necrosis
I + Zero None Prominent HW rosettes None
II + Low Low Present HW rosettes None
III +/- Moderate Moderate Low FW rosettes Rare
IV +/- High High Absent None Frequent


Tumor staging is an important guide for prognosis and therapy. Several staging systems, including Hymans (see Pathophysiology, above), Kadish, and TNM systems, have been proposed as a guide to choosing treatment modalities.

From a limited series of 17 patients, Kadish et al were the first to propose a staging classification for esthesioneuroblastoma (ENB).[15] ENBs were divided into 3 categories: groups A, B, and C. Group A is limited to tumors of the nasal fossa; in group B, extension is to the paranasal sinuses; and group C is defined as extension beyond the paranasal sinuses and nasal cavity.

Some authors have noted that effectively stratifying patients with the Kadish system can be difficult. Recognizing these inadequacies, Morita et al in 1993 published a revised Kadish system that redefined stage C (consisting of local disease spreading beyond the paranasal sinuses) and included a stage D (distant metastasis).[16]

In 1992, Dulguerov and Calceterra proposed a classification based on the tumor, node, metastasis (TNM) system, which is predicated on CT and MRI findings that can be identified before treatment.[17] Although this classification system has gained popularity, attempts have been made to further modify the Kadish system for ENB.

The TNM classification is as follows:

  • T1 - Tumor involving the nasal cavity and/or paranasal sinuses (excluding sphenoid), sparing the most superior ethmoidal cells
  • T2 - Tumor involving the nasal cavity and/or paranasal sinuses (including the sphenoid), with extension to or erosion of the cribriform plate
  • T3 - Tumor extending into the orbit or protruding into the anterior cranial fossa, without dural invasion.
  • T4 - Tumor involving the brain
  • N0 - No cervical lymph node metastasis
  • N1 - Any form of cervical lymph node metastasis
  • M0 - No metastasis
  • M1 - Distant metastases present


Grossly, esthesioneuroblastoma (ENB) appears as a gray to red mass in the nasal vault. The color usually is related to the extent of tumor vascularization, raising the possibility of profuse nasal bleeding following the biopsy procedure.

Taking a biopsy specimen should be deferred until completion of the radiologic studies to avoid swelling effects on accurate imaging and the inadvertent biopsy of other nasal tumors of neurogenic origin.

Biopsy and endoscopy should be performed under general anesthesia. The specimen should be sent for regular staining, as well as for immunohistochemistry and possibly electron microscopy.

Contributor Information and Disclosures

Michael Somenek, MD Physician, Facial Plastic and Reconstructive Surgery, Ruff Plastic Surgery

Michael Somenek, MD is a member of the following medical societies: Alpha Omega Alpha, Sigma Xi

Disclosure: Nothing to disclose.


Guy J Petruzzelli, MD, PhD, MBA, FACS Physician-in-Chief and Vice President of Oncology Programs, Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center; Professor of Surgery-Head, Neck, and Endocrine Surgery, Mercer University School of Medicine-Savannah Campus

Guy J Petruzzelli, MD, PhD, MBA, FACS is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Association for the Advancement of Science, American College of Surgeons, American Head and Neck Society, American Medical Association, Chicago Medical Society, North American Skull Base Society, Society of Surgical Oncology, Society of University Otolaryngologists-Head and Neck Surgeons, SWOG, American Association of Clinical Anatomists, American Society of Clinical Oncology, International Academy of Oral Oncology, International Head and Neck Scientific Group, Georgia Society of Otolaryngology-Head and Neck Surgery

Disclosure: Nothing to disclose.

Nicholas C Shera, PhD Freelance Medical/Scientific Writer

Disclosure: Nothing to disclose.

Thomas C Origitano, MD, PhD, FACS Professor and Chair, Department of Neurological Surgery, Medical Director, Neuroscience Service Line, Co-Director, Center for Cranial Base Surgery, Loyola University Medical Center

Thomas C Origitano, MD, PhD, FACS is a member of the following medical societies: American Association of Neurological Surgeons, American College of Surgeons, North American Skull Base Society, Congress of Neurological Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Jules E Harris, MD, FACP, FRCPC Clinical Professor of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Arizona Cancer Center

Jules E Harris, MD, FACP, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Society of Hematology, Central Society for Clinical and Translational Research, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Additional Contributors

Robert C Shepard, MD, FACP Associate Professor of Medicine in Hematology and Oncology at University of North Carolina at Chapel Hill; Vice President of Scientific Affairs, Therapeutic Expertise, Oncology, at PRA International

Robert C Shepard, MD, FACP is a member of the following medical societies: American Association for Cancer Research, American Association for Physician Leadership, European Society for Medical Oncology, Association of Clinical Research Professionals, American Federation for Clinical Research, Eastern Cooperative Oncology Group, Society for Immunotherapy of Cancer, American Medical Informatics Association, American College of Physicians, American Federation for Medical Research, American Medical Association, American Society of Hematology, Massachusetts Medical Society

Disclosure: Nothing to disclose.

  1. Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res. 1997 Jul-Aug. 17(4A):2683-706. [Medline].

  2. Zhang M, Zhou L, Wang DH, Huang WT, Wang SY. Diagnosis and management of esthesioneuroblastoma. ORL J Otorhinolaryngol Relat Spec. 2010. 72(2):113-8. [Medline].

  3. Wenig BM, Prasad ML, Dulguerov P. Neuroectodermal tumors. In: Barnes L, Eveson JW, Reichart P, and Sidransky D, WHO Classification of Tumors. 2005.

  4. Guled M, Myllykangas S, Frierson HF Jr, Mills SE, Knuutila S, Stelow EB. Array comparative genomic hybridization analysis of olfactory neuroblastoma. Mod Pathol. 2008 Jun. 21(6):770-8. [Medline].

  5. Mhawech P, Berczy M, Assaly M, Herrmann F, Bouzourene H, Allal AS, et al. Human achaete-scute homologue (hASH1) mRNA level as a diagnostic marker to distinguish esthesioneuroblastoma from poorly differentiated tumors arising in the sinonasal tract. Am J Clin Pathol. 2004 Jul. 122(1):100-5. [Medline]. [Full Text].

  6. Carney ME, O''Reilly RC, Sholevar B. Expression of the human Achaete-scute 1 gene in olfactory neuroblastoma (esthesioneuroblastoma). J Neurooncol. 1995 Oct. 26(1):35-43. [Medline].

  7. Theilgaard SA, Buchwald C, Ingeholm P. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol. 2003 Apr. 123(3):433-9. [Medline].

  8. Kane AJ, Sughrue ME, Rutkowski MJ, Aranda D, Mills SA, Buencamino R, et al. Posttreatment prognosis of patients with esthesioneuroblastoma. J Neurosurg. 2010 Aug. 113(2):340-51. [Medline].

  9. Magnavita N, Sacco A, Bevilacqua L, D'Alessandris T, Bosman C. Aesthesioneuroblastoma in a woodworker. Occup Med (Lond). 2003 May. 53(3):231-4. [Medline].

  10. Tseng J, Michel MA, Loehrl TA. Peripheral cysts: a distinguishing feature of esthesioneuroblastoma with intracranial extension. Ear Nose Throat J. 2009 Jun. 88(6):E14. [Medline].

  11. Rostomily RC, Elias M, Deng M, Elias P, Born DE, Muballe D, et al. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head Neck. 2006 Apr. 28(4):305-12. [Medline].

  12. Min KW. Usefulness of electron microscopy in the diagnosis of "small" round cell tumors of the sinonasal region. Ultrastruct Pathol. 1995 Sep-Oct. 19(5):347-63. [Medline].

  13. Argani P, Perez-Ordonez B, Xiao H. Olfactory neuroblastoma is not related to the Ewing family of tumors: absence of EWS/FLI1 gene fusion and MIC2 expression. Am J Surg Pathol. 1998 Apr. 22(4):391-8. [Medline].

  14. Hyams VJ, Batsakis JG, Michaels L. Olfactory neuroblastoma. In: Tumors of the Upper Respiratory Tract and Ear, Atlas of Tumor Pathology. Vol 25. Washington DC: Armed Forces Institute Press; 1988:. 240-8.

  15. Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer. 1976 Mar. 37(3):1571-6. [Medline].

  16. Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery. 1993 May. 32(5):706-14; discussion 714-5. [Medline].

  17. Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope. 1992 Aug. 102(8):843-9. [Medline].

  18. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001 Nov. 2(11):683-90. [Medline].

  19. Fitzek MM, Thornton AF, Varvares M. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. 2002 May 15. 94(10):2623-34. [Medline].

  20. Nichols AC, Chan AW, Curry WT, Barker FG, Deschler DG, Lin DT. Esthesioneuroblastoma: the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. Skull Base. 2008 Sep. 18(5):327-37. [Medline]. [Full Text].

  21. Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys. 2009 Feb 1. 73(2):424-32. [Medline].

  22. Sterzing F, Stoiber EM, Nill S, Bauer H, Huber P, Debus J, et al. Intensity Modulated Radiotherapy (IMRT) in the treatment of children and adolescents - a single institution''s experience and a review of the literature. Radiat Oncol. 2009 Sep 23. 4(1):37. [Medline]. [Full Text].

  23. Tselis N, Heyd R, Baghi M, Zamboglou N. Interstitial high-dose-rate-brachytherapy in advanced esthesioneuroblastoma. Laryngoscope. 2008 Nov. 118(11):2006-10. [Medline].

  24. Gupta S, Husain N, Sundar S. Esthesioneuroblastoma chemotherapy and radiotherapy for extensive disease: a case report. World J Surg Oncol. 2011 Oct 5. 9:118. [Medline]. [Full Text].

  25. Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, Jane JA, et al. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg. 2006 Feb. 132(2):134-8. [Medline].

  26. McElroy EA Jr, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery. 1998 May. 42(5):1023-7; discussion 1027-8. [Medline].

  27. Porter AB, Bernold DM, Giannini C, Foote RL, Link MJ, Olsen KD, et al. Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol. 2008 Nov. 90(2):201-4. [Medline].

  28. Koka VN, Julieron M, Bourhis J. Aesthesioneuroblastoma. J Laryngol Otol. 1998 Jul. 112(7):628-33. [Medline].

  29. Mishima Y, Nagasaki E, Terui Y, Irie T, Takahashi S, Ito Y, et al. Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma. Cancer. 2004 Sep 15. 101(6):1437-44. [Medline]. [Full Text].

  30. Turano S, Mastroianni C, Manfredi C, Biamonte R, Ceniti S, Liguori V, et al. Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine. J Neurooncol. 2010 May. 98(1):131-5. [Medline].

  31. Castelnuovo P, Bignami M, Delù G, Battaglia P, Bignardi M, Dallan I. Endonasal endoscopic resection and radiotherapy in olfactory neuroblastoma: our experience. Head Neck. 2007 Sep. 29(9):845-50. [Medline].

  32. Castelnuovo PG, Delù G, Sberze F, Pistochini A, Cambria C, Battaglia P, et al. Esthesioneuroblastoma: endonasal endoscopic treatment. Skull Base. 2006 Feb. 16(1):25-30. [Medline]. [Full Text].

  33. Folbe A, Herzallah I, Duvvuri U, Bublik M, Sargi Z, Snyderman CH, et al. Endoscopic endonasal resection of esthesioneuroblastoma: a multicenter study. Am J Rhinol Allergy. 2009 Jan-Feb. 23(1):91-4. [Medline].

  34. Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients. Laryngoscope. 2009 Jul. 119(7):1412-6. [Medline].

  35. Zanation AM, Ferlito A, Rinaldo A, Gore MR, Lund VJ, McKinney KA, et al. When, how and why to treat the neck in patients with esthesioneuroblastoma: a review. Eur Arch Otorhinolaryngol. 2010 Nov. 267(11):1667-71. [Medline]. [Full Text].

  36. Beitler JJ, Fass DE, Brenner HA, Huvos A, Harrison LB, Leibel SA, et al. Esthesioneuroblastoma: is there a role for elective neck treatment?. Head Neck. 1991 Jul-Aug. 13(4):321-6. [Medline].

  37. Rosenthal DI, Barker JL, El-Naggar AK. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004 Dec 1. 101(11):2567-73.

  38. Bradley PJ, Jones NS, Robertson I. Diagnosis and management of esthsioneuroblastoma. Curr OPin Otolaryngol Head Neck Surg. 2003. 11:112-118.

  39. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. Prog Clin Biol Res. 1994. 385:363-9. [Medline].

  40. Constantinidis J, Steinhart H, Koch M. Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000. Otolaryngol Head Neck Surg. 2004 May. 130(5):567-74.

  41. Devaney K, Wenig BM, Abbondanzo SL. Olfactory neuroblastoma and other round cell lesions of the sinonasal region. Mod Pathol. 1996 Jun. 9(6):658-63. [Medline].

  42. Dias FL, Sa GM, Lima RA. Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg. 2003 Nov. 129(11):1186-92. [Medline].

  43. Dulguerov P, Allal AS. Nasal and paranasal sinus carcinoma: how can we continue to make progress?. Curr Opin Otolaryngol Head Neck Surg. 2006 Apr. 14(2):67-72.

  44. Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer. 2001 Dec 15. 92(12):3012-29. [Medline].

  45. Frierson HF Jr, Mills SE, Fechner RE. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol. 1986 Nov. 10(11):771-9. [Medline].

  46. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, et al. Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study. Head Neck. 2005 Jul. 27(7):575-84. [Medline].

  47. Lund VJ, Howard D, Wei W. Olfactory neuroblastoma: past, present, and future?. Laryngoscope. 2003 Mar. 113(3):502-7. [Medline].

  48. Perez-Ordonez B, Caruana SM, Huvos AG. Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. Hum Pathol. 1998 Aug. 29(8):826-32. [Medline].

  49. Silva EG, Butler J, MacKay B, et al. Neuroblastomas and neuroendocrine carcinomas of the nasal cavity. A proposed new classification. Cancer. 2006. 50:2388-2405.

Esthesioneuroblastoma. Coronal CT scan of the orbits and sinuses shows a large, enhancing, and expansile mass occupying the ethmoid air cells that is invading the cribriform plate and breaking through to the left anterior cranial fossa. Image courtesy of Michael Lev, MD.
Esthesioneuroblastoma. A 39-year-old man presented with 1 month of decreased vision, left facial numbness, and swelling. Physical examination demonstrated left-sided exophthalmos and blindness. He had also lost his sense of smell. Contrast-enhanced T1-weighted MRI demonstrated a large lesion that originated in the paranasal sinuses and extended through the cribriform plate into the anterior cranial fossa. He underwent a bifrontal craniotomy for resection of this tumor.
Table. Histopathologic Grading According to Hyams [14]
Grade Lobular Architecture Preservation Mitotic Index Nuclear Polymorphism Fibrillary Matrix Rosettes Necrosis
I + Zero None Prominent HW rosettes None
II + Low Low Present HW rosettes None
III +/- Moderate Moderate Low FW rosettes Rare
IV +/- High High Absent None Frequent
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.